Rekha Hemrajani

Ms. Hemrajani is a senior executive with more than 20 years of biopharmaceutical industry experience. She currently serves as CEO (part time) and director of Jiya Acquisition Corp, where she led the $100 million initial public offering. Ms. Hemrajani has held senior management positions at numerous listed biopharmaceutical companies, including President, CEO and Director of Aravive, Inc., CFO and COO of Arcus Biosciences, Inc., and COO of RAPT Therapeutics (formerly FLX Bio), Inc. Ms. Hemrajani received a MBA from Northwestern University and a BS in economics and computer science from the University of Michigan. Ms. Hemrajani also serves as non-executive director of ALX Oncology Holdings, Inc.